TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02659527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga- PSMA-HBED-CC
Description: Patients will receive a dual-tracer PET/MRI scan. FEC and 68Ga-PSMA-HBED-CC, for tissue metabolism and surface marker expressions, as specific PET-tracers as well as multiparametric MRI methods (T2w, DCE, DWI) are used.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 68Ga- PSMA-HBED-CC
Description: Patients will receive a dual-tracer PET/MRI scan. FEC and 68Ga-PSMA-HBED-CC, for tissue metabolism and surface marker expressions, as specific PET-tracers as well as multiparametric MRI methods (T2w, DCE, DWI) are used.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biograph mMR, Siemens
Description: All PET-MRI examinations will be performed using a hybrid PET-MRI system (Biograph mMR, Siemens, Germany) capable of simultaneous data acquisition. The system consists of an MRI-compatible state-of the art PET detector integrated in a 3.0-T whole-body MRI scanner.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biograph mMR, Siemens
Description: All PET-MRI examinations will be performed using a hybrid PET-MRI system (Biograph mMR, Siemens, Germany) capable of simultaneous data acquisition. The system consists of an MRI-compatible state-of the art PET detector integrated in a 3.0-T whole-body MRI scanner.
Study: NCT00939809

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Urokinase-Derived Peptide A6
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01357265

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Seasonal Influenza Vaccine
Description: This phase II is performed as a multicenter study in adult and elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated flu vaccine during the vaccination visit, according to the study protocol (follow-up period: until day 22) .
Study: NCT01799499

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TC-3 hydrogel

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TC-3 hydrogel

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TC-3 hydrogel
Study: NCT00854594

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Role modeling in Shared medical appointments to Promote Establishing Collaborative Teams (ReSPECT)
Description: The intervention is designed to educate the clinicians at intervention CBOCs by modeling interprofessional team practices during SMAs for diabetes mellitus (DM) patients from each CBOC primary care provider's (PCP) patient panel. We hypothesize that this education at intervention CBOCs will improve interprofessional practices and overall quality care delivered to veterans.
Study: NCT01163214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerve Block
Description: Regional anesthetic nerve block using an indwelling femoral nerve catheter and a single shot sciatic nerve block using 0.5% ropivacaine.
Study: NCT00922714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: Intravenous glutamine supplementation (0.285 g/kg body weight/24 h)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline (placebo)
Description: NaCl 0.9 g/L
Study: NCT01960153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Tadalafil tablets, 20 mg to 40 mg per day x 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of tadalafil. Subjects will take one tablet once per day and will be titrated to two tablets once per day after one week. Subjects are on study drug for the duration of the trial.
Study: NCT02725866

Intervention type: DRUG
Intervention: Paritaprevir/ritonavir/ombitasvir
Description: Co-formulated tablet

Intervention type: DRUG
Intervention: Dasabuvir
Description: Tablet

Intervention type: DRUG
Intervention: Ribavirin
Description: Tablet
Study: NCT03455660

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT02723084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493/ABT-530
Description: Co-formulated tablet
Study: NCT02723084

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sofosbuvir (SOF)
Description: Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin (RBV)
Description: Capsule
Study: NCT04377360

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Diffusing Alpha-emitter Radiation Therapy
Description: Diffusing Alpha-emitter Radiation Therapy (DaRT) is a method of delivering interstitial brachytherapy, based on the interstitial intratumoral placement of an encapsulated Radium-224 source (3.7 days half-life). These sources release short-lived alpha-emitting atoms into the tumor microenvironment by recoil. As the radioisotope has a short half-life, the majority of radiation absorption happens in the tumor.
Study: NCT04930679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andiabet
Description: Each hard capsule includes: 200mg Gynostemma Pentaphyllum Leaf, 200mg Largerstroemia Speciosa Leaf, 133mg Anemarrhena Asphodeloides Whole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andiabet
Description: Each hard capsule includes: 200mg Gynostemma Pentaphyllum Leaf, 200mg Largerstroemia Speciosa Leaf, 133mg Anemarrhena Asphodeloides Whole
Study: NCT00266799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (SCH 200746)
Description: pegylated liposomal doxorubicin (50 mg/m\^2 q 28 days) was administered intravenously until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: capecitabine (1250 mg/m\^2 BID x 14 days q 21 days) in tablets of 150 mg and 500 mg was administered orally, until disease progression or unacceptable toxicity
Study: NCT01116895

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 22811
Description: Oral solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 22811
Description: Oral solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 22811
Description: Oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03718728

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind&Life
Description: Acceptance and mindfulness-based group intervention program.
Study: NCT02593318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaloacetate (OAA) 1g
Description: Pills to be taken orally in 500mg dose two times per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaloacetate (OAA) 2g
Description: Pills to be taken orally in 1000mg dose two times per day.
Study: NCT05281055

Intervention type: PROCEDURE
Intervention: Endovascular thrombectomy
Description: Timely thrombectomy for acute ischemic stroke patients with large vessel occlusion by either stent retriever, thrombosuction, others, or combination methods.
Study: NCT01352312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine at the dose of 50 mg/m2 (or 70 or 90 or 40 mg/m2 depending on the dose level) daily on day 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Description: Pentostatin 4 mg/m2 on day 1 of each cycle. For patients with estimated or measured glomerular filtration rate (GFR) 30 to 60 ml/min/m2 pentostatin will be administered at the reduced dose of 2 mg/m2 on day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Ofatumumab 300 mg on day 2 of first cycle. Subsequently, from cycle 2 to 6, ofatumumab 1000 mg on day 2 will be administered.
Study: NCT04228094

Intervention type: OTHER
Intervention: TDApp1: an eHealth intervention
Description: TDApp1 is a tool that uses GRADE heuristics to formulate participatory, individualized and automated therapeutic recommendations for patients with Attention Deficit Hyperactivity Disorder
Study: NCT01918566

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Single intragastric instillation of 75g Glucose in 300ml tap water with 450ppm lactisole

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 25g Fructose in 300ml tap water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 75g glucose in 300ml tap water with 600pmol/kg/min exendin 9-39

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: 300ml tap water with 450ppm lactisole
Study: NCT02729909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: Lubiprostone capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lubiprostone placebo-matching capsules
Study: NCT02699073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regorafenib
Description: 160mg once daily during 3 weeks followed by 1 week off therapy.~Regorafenib will be taken until disease progression according to the CHOI and RECIST1.1 criteria, death or inacceptable toxicity.
Study: NCT00006760

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: subcutaneously or IV over 15-30 minutes beginning 24-36 hours after completion of vinorelbine and continuing daily until blood counts recover.
Study: NCT01605721

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XIENCE PRIMETM everolimus-eluting coronary stent
Description: Active prospective registration of patients receiving the following stent~: XIENCE PRIMETM
Study: NCT02085330

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Description: 100%, 2 ATA, 90 minutes
Study: NCT06099834

Intervention type: OTHER
Group type: OTHER
Intervention: Patients selection
Description: Patient selection were selected according to selected criteria.

Intervention type: OTHER
Group type: OTHER
Intervention: Implnat placement
Description: dental implants were applied as recommended by the manufacturer.

Intervention type: OTHER
Group type: OTHER
Intervention: Recall visits
Description: Following the operations, the stability of the dental implants was measured at the 1st (T1), 4th (T4), and 12th (T12) weeks using Periotest (Periotest M, Modautal/Germany) and Osstell (Osstell AB-W\&H, Sweden) devices.
Study: NCT00698334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INH, Rifampicin, Ethambutol and Pyrazinamide
Description: Directly Observed Treatment Short-course; Thrice weekly (INH 600 mg, Rifampicin 450 mg \[600 mg if more than 59 kg\], Ethambutol 1200 mg, Pyrazinamide 1500 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INH, Rifampicin, Ethambutol and Pyrazinamide
Description: Directly Observed Treatment Short-course; Thrice weekly (INH 600 mg, Rifampicin 450 mg \[600 mg if more than 59 kg\], Ethambutol 1200 mg, Pyrazinamide 1500 mg)
Study: NCT03012867

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diben, Fresenius Kabi
Description: Patients receive Diben continously for 7 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fresubin original fibre, Fresenius Kabi
Description: Patients receive Fresubin original fibre continously for 7 days
Study: NCT01892891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VBY-036
Description: Cathepsin S inhibitor
Study: NCT00991406

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES
Description: Surface stimulation to contract the muscles in the lower extremity
Study: NCT03450733

Intervention type: DEVICE
Intervention: Wright Medical Technology Metal-on-Metal Total Hip System
Description: Subjects in Group 1 previously implanted prior to the study start date will be identified from Investigator records. Collected data will be evaluated in aggregate and cross-sectioned by year of implantation. Subjects will be cross-sectioned by the time that has elapsed between implantation and the initial visit (e.g. 5 years, 6 years) using contiguous visit windows (number of years + 6 months). Subject data will be grouped in order to create cross-sectional epochs of ≤ 8 years and \> 8 years.
Study: NCT03824587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenapanor
Description: Active Drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive Drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate Binder Agents
Description: standard of care phosphate binder use at study entry was maintained throughout the entire study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phosphate Binder Agents
Description: standard of care phosphate binder use at study entry was maintained throughout the entire study
Study: NCT02501525

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RIRS with ureteral access sheath
Description: Ureteral access sheath will be used during RIRS.
Study: NCT00730782

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PfAMA-1-FVO[25-545]
Description: Subcutaneous vaccination of 0.5ml of two dosage 10 and 50ug PfAMA1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PfAMA-1-FVO[25-545]
Description: Subcutaneous vaccination of 0.5ml of two dosage 10 and 50ug PfAMA1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PfAMA-1-FVO[25-545]
Description: Subcutaneous vaccination of 0.5ml of two dosage 10 and 50ug PfAMA1
Study: NCT01028508

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lithium and Venlafaxine
Description: Drug: VLF Target dose 225 mg/day Drug: Li Target serum concentration 0.7 mEq/l

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ECT
Description: Procedure: ECT RUL ultra brief pulse ECT, 4 treatments in one month and then treatment on an as-needed basis for 5 months Drug: VLF Target dose 225 mg/day Drug: Li Target serum concentration 0.7 mEq/l
Study: NCT03303404

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambulatory (24-hour) Blood Pressure
Description: Unlike casual blood pressure measurements, 24-hour ambulatory blood pressure monitoring provides an insight into blood pressure changes in everyday life and an estimate of the overall blood pressure load exerted on the cardiovascular system over 24 hours. Blood pressure recordings over a 24-hour period of normal daily activity will be made using a noninvasive ambulatory monitor (Spacelabs, Redlands, WA). The ambulatory system will be calibrated against a mercury sphygmomanometer, and the cuff will be programmed to inflate automatically every 15 min from 6 AM to 11 PM and every 20 min between 11 PM and 6 AM. For each individual subject, the nighttime period will be defined as the time when the subject goes to bed at night until rising in the morning. Daytime will be defined as the remainder of the 24-hour period. Daytime and nighttime states will be monitored by an Actiwatch (Mini-MItter, Bend, OR), a watch-like device placed on the wrist that measures gross motor activity.
Study: NCT00308503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eplivanserin (SR46349)
Description: oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration
Study: NCT03462550

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal mask
Description: LMA insertion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal mask
Description: LMA insertion
Study: NCT02522286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ask 3 Questions
Description: Participants were asked to bring an Ask 3 questions flyer into their appointment to use if they needed to make a choice about their health care during their appointment. These 3 questions have been shown to help patients make more informed decisions about their healthcare.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ask 3 Questions
Description: Participants were asked to bring an Ask 3 questions flyer into their appointment to use if they needed to make a choice about their health care during their appointment. These 3 questions have been shown to help patients make more informed decisions about their healthcare.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Open Communication
Description: Open Communication includes a combination of interventions. 1) Participants used a Visit Companion Booklet to write out issues they would like to discuss with their physician during their appointment before showing up. They were also asked to write out any next steps decided on during their appointment and to repeat back to their doctor what they wrote before leaving.~2) Patients watched a short, informational cartoon video to better understand the Visit Companion Booklet.~3) Participating physicians received a training through the use of a Standardized Patient Instructor as a means of providing convenient, individualized training on communication techniques. Dyads (physicians and their medical assistants) were trained on how to incorporate the Visit Companion Booklet into workflow.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Open Communication
Description: Open Communication includes a combination of interventions. 1) Participants used a Visit Companion Booklet to write out issues they would like to discuss with their physician during their appointment before showing up. They were also asked to write out any next steps decided on during their appointment and to repeat back to their doctor what they wrote before leaving.~2) Patients watched a short, informational cartoon video to better understand the Visit Companion Booklet.~3) Participating physicians received a training through the use of a Standardized Patient Instructor as a means of providing convenient, individualized training on communication techniques. Dyads (physicians and their medical assistants) were trained on how to incorporate the Visit Companion Booklet into workflow.
Study: NCT01700855

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: non-electroacupuncture
Description: The same procedure as electroacupuncture except stimulation
Study: NCT03718728

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard
Description: Personalized diet and physical exercise recommendations.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Personalized diet and physical exercise recommendations.
Study: NCT02054624

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle intervention
Description: The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by group telephone call.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive two phone calls per month from their group leader for the first 6 months, and one phone call per month for the next 6 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education control
Description: The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by email.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive a specially prepared newsletter two times per month. The newsletter will contain educational information about proper eating and physical activity. The newsletters will include low-fat and low-calorie recipes, along with tip sheets that describe strategies to help them maintain lost weight.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual
Description: The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by on-on-one telephone call.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive two phone calls per month from their group leader for the first 6 months, and one phone call per month for the next 6 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: All Groups
Description: All participants will receive the following: Questionnaires, height, weight, waist measurement, blood pressure, heart rate, electrocardiogram, blood sample, urine sample, urine pregnancy test (for females only), 400 meter walking test

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: All Groups
Description: All participants will receive the following: Questionnaires, height, weight, waist measurement, blood pressure, heart rate, electrocardiogram, blood sample, urine sample, urine pregnancy test (for females only), 400 meter walking test

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: All Groups
Description: All participants will receive the following: Questionnaires, height, weight, waist measurement, blood pressure, heart rate, electrocardiogram, blood sample, urine sample, urine pregnancy test (for females only), 400 meter walking test
Study: NCT01433328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Lidocaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01172795

Intervention type: BEHAVIORAL
Intervention: Relaxation session
Description: 30 minutes relaxation session (audiotape)

Intervention type: BEHAVIORAL
Intervention: Relaxation session
Description: 30 minutes relaxation session (audiotape)

Intervention type: BEHAVIORAL
Intervention: Relaxation session
Description: 30 minutes relaxation session (audiotape)

Intervention type: BEHAVIORAL
Intervention: Neurocognitive test battery
Description: the psychomotor vigilance task, span task and the stroop task on computer
Study: NCT00006760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: V over 24 hours on days 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Description: IV over 6-10 minutes on days 1 and 5.
Study: NCT02501525

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RIRS without ureteral access sheath
Description: Ureteral access sheath will not be used during RIRS.
Study: NCT02919514

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical training on hard surface.
Description: Physical training on hard surface.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical training on hard surface.
Description: Physical training on hard surface.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical training on sand surface.
Description: Physical training on sand surface.
Study: NCT01172795

Intervention type: BEHAVIORAL
Intervention: Neurocognitive test battery
Description: the psychomotor vigilance task, span task and the stroop task on computer

Intervention type: BEHAVIORAL
Intervention: Neurocognitive test battery
Description: the psychomotor vigilance task, span task and the stroop task on computer